Crossmark

Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5

Crossref DOI link: https://doi.org/10.1186/s40425-016-0136-y

Published Online: 2016-06-21

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Eng, Jason W.-L.

Mace, Thomas A.

Sharma, Rohit

Twum, Danielle Y. F.

Peng, Peng

Gibbs, John F.

Pitoniak, Rosemarie

Reed, Chelsey B.

Abrams, Scott I.

Repasky, Elizabeth A.

Hylander, Bonnie L.
Funding

Funding for this research was provided by:

National Institutes of Health (R01 CA10888801A1, R01 CA140622)

NY Dept of Health, NYSTEM (NO8G-370)

Roswell Park Alliance Foundation, Roswell Park Cancer Institute

American Medical Association Foundation (Seed Grant)

National Institutes of Health (T32 CA085183)

National Institutes of Health (Comprehensive Cancer Center Support Grant CA016056)